ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs MXN
16.53105
-0.15%
Brent Oil
82.755
-0.93%
Bitcoin
70,971.96
-0.67%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vertex Pharmaceuticals Inc (VRTX)

  7. Vertex Pharmaceuticals Inc (VRTX) Noticias

VRTX

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VRTX
FechaHoraFuenteTítuloSímboloCompañía
20/05/202414:32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
20/05/202407:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
20/05/202407:25Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:VRTXVertex Pharmaceuticals Inc
17/05/202415:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
17/05/202415:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
15/05/202409:30Business WireJennifer Schneider Elected to Vertex Board of DirectorsNASDAQ:VRTXVertex Pharmaceuticals Inc
07/05/202415:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRTXVertex Pharmaceuticals Inc
07/05/202406:46IH Market NewsDisney Slashes Streaming Losses, UBS shoots up 9% as profit triples expectations, and More in EarningsNASDAQ:VRTXVertex Pharmaceuticals Inc
06/05/202415:01Business WireVertex Reports First Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
06/05/202407:09IH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:VRTXVertex Pharmaceuticals Inc
26/04/202410:43Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and OlderNASDAQ:VRTXVertex Pharmaceuticals Inc
22/04/202423:45PR Newswire (Canada)VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETESNASDAQ:VRTXVertex Pharmaceuticals Inc
18/04/202407:00Business WireVertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic PainNASDAQ:VRTXVertex Pharmaceuticals Inc
11/04/202406:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:VRTXVertex Pharmaceuticals Inc
10/04/202415:01Business WireVertex Enters Into Agreement to Acquire Alpine Immune SciencesNASDAQ:VRTXVertex Pharmaceuticals Inc
09/04/202415:05Business WireVertex to Announce First Quarter 2024 Financial Results on May 6NASDAQ:VRTXVertex Pharmaceuticals Inc
01/04/202410:00PR Newswire (Canada)Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
01/04/202410:00PR Newswire (Canada)Vertex annonce que la présentation de drogue nouvelle d'Exagamglogène Autotemcel (exa-cel) a été acceptée pour évaluation prioritaire par Santé Canada pour le traitement de l'anémie falciforme et de la bêta-thalassémie dépendante des transfusionNASDAQ:VRTXVertex Pharmaceuticals Inc
01/04/202407:00Business WireVertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney DiseaseNASDAQ:VRTXVertex Pharmaceuticals Inc
21/03/202407:00Business WireVertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:VRTXVertex Pharmaceuticals Inc
23/02/202406:10Business WireVertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and OlderNASDAQ:VRTXVertex Pharmaceuticals Inc
20/02/202415:05Business WireVertex to Participate in Upcoming Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
13/02/202400:59Business WireEuropean Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
09/02/202417:19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VRTXVertex Pharmaceuticals Inc
06/02/202405:14IH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNASDAQ:VRTXVertex Pharmaceuticals Inc
05/02/202415:06Business WireVertex Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
05/02/202415:01Business WireVertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
30/01/202405:28Business WireVertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute PainNASDAQ:VRTXVertex Pharmaceuticals Inc
25/01/202412:48Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VRTXVertex Pharmaceuticals Inc
17/01/202407:00Business WireVertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5NASDAQ:VRTXVertex Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VRTX

Su Consulta Reciente

NYSE
MCD
McDonalds
USOTC
BNPQY
BNP Paribas (QX)
NYSE
XOM
Exxon Mobil
NYSE
AXP
American Express
FX
EURMXN
Euro vs MXN
COIN
ETHUSD
Ethereum
USOTC
BASFY
BASF (QX)
USI
USTECH100
US Tech 100
AMEX
XLE
Energy Select Sector SPDR
SPI
SP500
S&P 500
AMEX
SPY
SPDR S&P 500
NYSE
NKE
Nike
COIN
SOLUSD
Solana
AMEX
XLF
Financial Select Sector
NYSE
JPM
JP Morgan Chase
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados